FABASOFT
21.9.2021 15:05:26 CEST | Business Wire | Press release
Siemens Energy is using Fabasoft Approve as the process-driven quality management solution for its Power Transformer segment. The global rollout of Fabasoft Approve is scheduled for upwards of 3,000 users following the successful completion of pilot projects at the two largest transformer plants in Weiz (Austria) and Nuremberg (Germany).
The challenge for Siemens Energy was to implement a cross-plant quality management tool in one network with 14 locations in eight countries and to digitally map its existing processes. Thanks to its wide range of customization options and high degree of usability, Fabasoft Approve made a convincing case in the multi-stage selection process and stood out as the high-performance platform of choice for computer-aided quality (CAQ) processes. The cloud-based solution offers comprehensive complaint management that can even be handled from a smartphone or tablet – for both in-house use and remote use at the customer’s site. Allocating the necessary immediate, corrective, and preventive actions is a workflow-driven process that can be tracked at any time.
You can find further information in the case study “Achieving predictive quality with Fabasoft Approve cross-plant quality management software”
“The overarching goal of our collaboration with Fabasoft is to achieve data-based prediction for product and process-related quality. Our new cross-plant quality management software affords us the transparency to make the right decisions and proactively avoid potential errors in the future. This way, we can be certain that we’re optimizing both our error costs and the level of customer satisfaction,” explains Stefan Klaassen, Head of Power Transformers, Siemens Energy.
“As a cross-plant quality management solution, Fabasoft Approve supplies all of the relevant product and process data. Thanks to its powerful analysis capabilities, any user can conduct analyses on quality issues with just a few mouse clicks. We are thrilled to be able to play a significant role in data-driven forecasting with Fabasoft Approve," adds Andreas Dangl, Business Unit Executive for Cloud Services at Fabasoft.
About Fabasoft Approve
Fabasoft Approve is a cloud-based off-the-shelf product for managing technical data and documents in an industrial setting. The standard solution integrates all project partners on a secure, scalable, and highly customizable platform. Creating and editing documents, as well as review, release, and approval processes are achieved efficiently and traceably with significantly less manual effort.
About Siemens Energy
With some 91,000 employees, Siemens Energy operates globally along the entire energy value chain. Its products include gas turbines, steam turbines, generators, transformers, and compressors. The company’s Power Transformer segment manufactures the largest transformers for substations located throughout the world.
About Fabasoft
Fabasoft is among the leading software product companies and cloud service providers in Europe for digital document management as well as electronic document, process, and records management.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005066/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom